Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 5 of 5 for “"tail-flick test"”.
-
An analysis of the role of midbrain dopamine systems in the suppression of tonic pain
… the midbrain induces analgesia in the formalin test for tonic pain. The present thesis explored in more depth the role of SP-DA interactions in the suppression of tonic pain, and examined whether the activation of midbrain DA neurons by endogeneous SP might be a mechanism underlying …
-
Secondary Metabolites from Otanthus maritimus, Stachys glutinosa and Withania somnifera: Isolation, Structure Elucidation and Interactions with Cannabinoid and Opioid Systems
… nociceptive activity of xanthomicrol in the tail flick test. Our data demonstrated that pretreatment of xanthomicrol inhibited morphine-‐induced anti-‐nociception in the tail flick test, suggesting an antagonistic effect at μ opioid receptor. As regards WSE and WSAE, the results of the …
-
Neurosteroids: endogenous analgesics?
… also performed using von Frey filaments and the tail flick test to examine mechanical and thermal nociception.<br/><br/>Recordings from the spinal cord, the thalamus and the cerebral cortex revealed that the decay time of miniature inhibitory postsynaptic currents are significantly reduced with …
-
Molecular Mechanisms by Which HSP90 Inhibition in the Spinal Cord Enhances Opioid Receptor Signaling
… to enhanced opioid signaling and pain relief. We tested this hypothesis using the AMPK activators AICAR and PT1 (i.t) and EGFR activator EGF (i.t) and found they decreased 17-AAG-enhanced morphine (subcutaneous, SC) antinociception in the tail flick test and paw-incision pain model in both male …
-
Ultra-Low Dose Antagonist Effects on Cannabinoids and Opioids in Models of Pain: Is Less More?
… 1, separate groups of Long Evans rats were tested for antinociception following an injection of vehicle, the cannabinoid agonist WIN 55 212-2 (WIN), the opioid antagonist naltrexone (an ultra-low or a high dose), or a combination of WIN and naltrexone doses. Ultra-low dose naltrexone …